SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IOVA

Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · USD
Healthcare · Biotechnology
$7.48-$0.05 (-0.66%)
 
Market cap
$3.46B
Insider Score
Analyst consensus
Market Cap$3.46B+206.6%
Revenue (ttm)$378.98M
Net Income-$220.54M
EPS-$0.49
Shares Out462.66M
PE Ration/a
Forward PE-65.68
Dividendn/a
Ex-Dividend Daten/a
Volume6,994,305
Open$7.46
Previous Close$7.53
Day's Range$7.29 - $7.66
52-Week Range$2.08 - $15.37
Beta0.84
AnalystsBuy
Price Target$14.50(+93.85%)
Earnings DateNov 5, 2026

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.

Address
300 Rouse Blvd., Philadelphia, PA, 19112, United States
Market Cap
3.46 billion
Employees
975
Industrial Classification
Biotechnology

Analyst consensus

Moderate Buy
5 Buy2 Hold0 SellAvg target $12.00 (+60.4%)

7 firms rating IOVA in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-0.66%
5 Days
-7.54%
1 Month
-49.66%
6 Months
+111.30%
1 Year
+206.56%

$IOVA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IOVA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IOVA's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IOVA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

IOVA Revenue by Segment or Geography

$121.47MTotal
Amtagvi$101.60M83.64%
Proleukin$19.87M16.36%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New IOVA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IOVA from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IOVA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
85
News & Sentiment
38% of score
72

News check: Q3 earnings beat with AMTAGVI sales growth, 2027 lung cancer filing target, lifileucel Fast Track status, and positive pipeline progress drive bullish sentiment.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.47%
PTHInvesco Dorsey Wright Healthcare Momentum ETF2.75%
IDNAiShares Genomics Immunology and Healthcare ETF2.75%
BBPVirtus Biotech ETF2.55%
HYPGolden Eagle Dynamic Hypergrowth ETF2.40%
MOONDirexion Moonshot Innovators ETF1.95%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF1.81%
CANCTema Oncology ETF1.72%
BUZZVanEck Social Sentiment ETF1.65%
XBIState Street SPDR S&P Biotech ETF0.87%
WDNAWisdomTree BioRevolution Fund0.63%
QQQSInvesco NASDAQ Future Gen 200 ETF0.56%

Weight is the stock’s share of each fund’s holdings.